Riskpilot← Back to searchSign inGet full accessPharmacuum Sverige AB
ABActiveOrg 5592135288Sörmon 106Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20191 employees
Revenue 2024
SEK 925K
-19% vs 2023
EBITDA margin
-14.8%
-154% vs 2023
Equity ratio
32.3%
Financial strength
Net profit 2024
SEK -191K
-187% vs 2023
| Revenue | SEK 925K | -19% |
| EBITDA | SEK -137K | -154% |
| Net profit | SEK -191K | -187% |
| Total assets | SEK 765K | -30% |
| Equity | SEK 247K | -44% |
| Employees | 1 | — |
Legal name
Pharmacuum Sverige AB
Org number
5592135288
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
31 juli 2019
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolagets verksamhet skall vara att bedriva utveckling, tillverkning och handel med läkemedel, läkemedelsnära produkter, medicintekniska produkter, djurfoder samt produkter till djur.
Address
Sörmon 106
Email
urban.edman@pharmacuum.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 3 | 23 | 603 | 1 140 | 925 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −716 | −659 | −245 | 253 | −137 |
| Depreciation & amort. | −42 | −30 | −30 | −30 | −17 |
| EBIT | −758 | −689 | −275 | 223 | −154 |
| Net financials | −2 | — | — | −3 | −36 |
| Profit before tax | −760 | −690 | −276 | 220 | −191 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −760 | −690 | −276 | 220 | −191 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 339 | 435 | 837 | 1 092 | 765 |
| Equity | 52 | 44 | 218 | 438 | 247 |
| Long-term debt | 270 | 282 | 433 | 406 | 280 |
| Short-term debt | 17 | 109 | 185 | 248 | 238 |
| Total debt | 287 | 391 | 618 | 654 | 518 |
EBITDA margin
-14.8%
This company
15.8%
Market median
-194% vs market
20202024
Equity ratio
32.3%
This company
38.2%
Market median
+15% vs market
20202024
Return on equity
-77.3%
This company
18.4%
Market median
-520% vs market
20202024
Net profit margin
-20.6%
This company
8.1%
Market median
-354% vs market
20202024
Asset turnover
1.21×
This company
1.12×
Market median
+8% vs market
20202024
Debt / equity
2.10×
This company
0.62×
Market median
-239% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2019-07-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
UG Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Pharmacuum Sverige AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Urban Gunnar Edman | Chief Executive Officer | 0 companies |
| Carl Peter Danielson | Deputy Board Member | 0 companies |